NATUREX : Number of shares and voting rights as at 31 January 2016
Article L.233-8-II of Commercial Law (Code de commerce) and
Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF – Autorité des Marchés Financiers)
|Total number of outstanding shares forming the capital
- 9,238,850 ordinary shares under ISIN FR0000054694
- 2,690 shares issued from stock-options under ISIN FR0000054694
|Number of shares with double voting rights||2,099,889|
|Total number of gross voting rights||11,341,429|
|Number of shares without voting rights
- 3,918 bearer shares in the frame of the liquidity contract
|Total number of exercisable voting rights*||11,337,511|
*Exercisable voting rights = total number of voting rights – number of shares without voting rights
You can receive all financial information of Naturex free of charge by signing up at: www.naturex.com
|Results – FY 2015||30 March 2016|
|SFAF Analysts Meeting
|31 March 2016
21 June 2016
Naturex has been listed since October 1996 on Euronext in Paris, Segment B
Total number of shares comprising the share capital: 9,241,540 (Janvier 2016)
Naturex is a component of the CACT, Enternext CAC PEA-PME 150, CAC Small & Mid, CAC Small, Gaïa Index.
Naturex is eligible for the "long only" Deferred Settlement Service (SRD) and French equity plans (PEA and PEA-PME).
Naturex established a Sponsored Level 1 American Depositary Receipt (ADR) program in the United States. Under this facility, Naturex's ADRs are traded over-the-counter in the United States under the symbol NTUXY.
TICKER: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP - DR SYMBOL: NTUXY
Naturex is the global leader in speciality plant-based natural ingredients. The Group is organised around three strategic markets (Food & Beverage, Nutrition & Health and Personal Care) and produces and markets speciality plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
Naturex's head office is based in Avignon. The company employs 1,500 people with 8 sourcing offices located throughout the world and high-performance manufacturing operations across 15 sites in Europe, Morocco, the United States, Brazil, Australia and India. It also has a global commercial presence through a dedicated network of sales offices in more than 20 countries.
Head of Investor Relations
Tel.: +33 (0)4 90 23 78 28
|Anne Catherine Bonjour
Actus Finance Press Relations
Tel.: +33 (0)1 53 67 36 93
Information relative au nombre total de droits de vote et d'actions composant le capital :
Full and original press release in PDF: